DAVID SHARP: Open Payments
NPI 1932117470 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,827 in 216 payments from 38 companies in 2025. Trend: 2023 $3,871 · 2024 $3,855 · 2025 $3,827
Food & beverage: $3,745Education: $82
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 16 | $365 |
| ABBVIE INC. | 23 | $364 |
| Novartis Pharmaceuticals Corporation | 25 | $353 |
| Antares Pharma, Inc. | 29 | $331 |
| Novo Nordisk Inc | 21 | $299 |
| Lilly USA, LLC | 16 | $285 |
| PFIZER INC. | 12 | $209 |
| Gilead Sciences, Inc. | 11 | $208 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $165 |
| Regeneron Healthcare Solutions, Inc. | 2 | $141 |
Products named: LEQVIO, XYOSTED, OTEZLA, NURTEC ODT, VRAYLAR, Ozempic, EVKEEZA, REPATHA.
Industry payments across NE — which companies pay providers there.
